TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
A phase 3 trial of TQB2930 and Trastuzumab in HER2-positive breast cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
Overview
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer is a phase 3 interventional study registered as NCT07047365 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 416 participants planned, started 2025-07-25 and due to reach its primary completion in 2028-06. Interventions recorded: TQB2930+ chemotherapy and Trastuzumab+ chemotherapy.
Similar pages
not linked directly; found by shared links- TrialClinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Shares TQB2930, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialA Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer and the tag pipeline.
- TrialA Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Shares TQB2930, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Shares Trastuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialA Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Shares Trastuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Trastuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialStudy of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Shares Trastuzumab, HER2-positive breast cancer and the tag pipeline.